

p53 is known as the 'guardian of the genome' and plays a key role in regulating cell proliferation and apoptosis




Inactivation of **p53** is a central mechanism for tumors to escape cell death




Brigimadlin is a potent, orally available small molecule investigational drug that binds to MDM2 and blocks the MDM2-p53 interaction, restoring p53 function

Targeting MDM2 with brigimadlin



Brigimadlin may also promote a pro-immunogenic tumor microenvironment to help immune destruction of tumor cells



Here we present data from the first 12 patients with biliary tract cancer (BTC) treated with brigimadlin in two ongoing Phase la/lb studies (data cut-off: Patients 1–10, December 2022; Patients 11–12, February 2023), and safety results in the overall populations

What are the aims of the two studies?




Assess safety, tolerability, and RP2D of brigimadlin, both as a monotherapy and in combination with ezabenlimab



Investigate antitumor activity in patients with advanced TP53wt, **MDM2-amplified** tumors (*TP53*wt only for Cohort 1 in 1403-0002)

What are the study designs?





are consistent with the safety profile seen in the overall population

Monotherapy study (Q3W) Combination study

Efficacy of brigimadlin +/- ezabenlimab in patients with BTC

Best response among patients with BTC who received either brigimadlin as monotherapy, or in combination with ezabenlimab (n=12)





DoT* (exposure; months)

*Time from first to last drug administration (D1Q3W); dose could be delayed due to AE up to 63 davs.

In summary

Treatment of brigimadlin +/- ezabenlimab in patients with BTC showed:



A tolerable safety profile



Promising preliminary antitumor activity



Brightline-2, a Phase IIa/b trial in patients with BTC, is currently open for recruitment (NCT05512377)

Manuscript Authors Noboru Yamamoto, Anthony Tolcher, Navid Hafez, Iwona Lugowska, Rodryg Ramlau, Teresa Macarulla, Junxian Geng, Jian Li, Michael Teufel, Angela Märten, Patricia LoRusso

Disclosures This study was funded by Boehringer Ingelheim. This summary is based on the manuscript, entitled "Efficacy and safety of the MDM2-p53 antagonist brigimadlin in patients with advanced biliary tract cancer". The authors were fully responsible for all content and editorial decisions of the associated manuscript.

Medical writing support for the development of this infographic summary was provided by Steven Kirkham, PhD, of Ashfield MedComms, an Inizio Company, and funded by Boehringer Ingelheim.



Disclaimer: These compounds are investigational agents and have not been approved by any regulatory authority

Supplementary Figure 1. An infographic summary of the case series manuscript entitled 'Efficacy and safety of the MDM2–p53 antagonist brigimadlin (BI 907828) in patients with advanced biliary tract cancer'.

Abbreviations: AEs, adverse events; BTC, biliary tract cancer; CD8, cluster of differentiation 8; DoT, duration of treatment; D1/8, Day 1/8; DLT, dose-limiting toxicity; MDM2, murine double minute 2 homolog; MTD, maximum tolerated dose; p53, protein 53; PD, progressive disease; PD-1, programmed cell death protein 1; PFS, progression-free survival; PK, pharmacokinetics; PR, partial response; pts, patients; Q3W, every three weeks; RP2D, recommended Phase II dose; SD, stable disease; TP53, tumor protein 53; TRAE, treatment-related AE; Treg, regulatory T-cell; WBC, white blood cell; wt, wild-type